Hemab Therapeutics Holdings
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 year.
- Recent price momentum is -18.5% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 7.1% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 39.86
- Open
- 39.50
- Day range
- 38.77 - 40.19
- Avg price
- 39.42
- Volume
- 347.02K
- Turnover
- 13.68M
- Turnover ratei
- 1.63%
- Volume ratioi
- 1.05
- Amplitudei
- 3.56%
- 52-week rangei
- 23.00 - 55.42
Valuation
- P/Ei
- -27.17
- P/E (TTM)i
- -19.64
- P/Bi
- 4.28
- EPSi
- -1.45
- Book value / shi
- 9.19
- Net profit
- -67.57M
- Net assets
- 429.27M
Share structure
- Market cap
- 1.84B
- Float capi
- 835.96M
- Shares out
- 46.73M
- Float sharesi
- 21.28M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2026-05-01
29.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-1.76M net over the window
Short interest
- Shares short
- 3.31M
- % of floati
- 7.08%
- Days to coveri
- 7.31
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Hemab Therapeutics Holdings (COAG)?
Hemab Therapeutics Holdings last traded at 39.29. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Hemab Therapeutics Holdings's market cap?
About 1.84B.
What is the P/E ratio of Hemab Therapeutics Holdings?
The trailing twelve-month P/E is -19.64. The Valuation tab shows it against the stock's own five-year range.
Does Hemab Therapeutics Holdings pay a dividend?
Hemab Therapeutics Holdings does not currently pay a regular dividend.
Is Hemab Therapeutics Holdings a buy according to analysts?
The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 64.00, which implies 62.9% upside from the current price. This is not investment advice.
What is Hemab Therapeutics Holdings's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Hemab Therapeutics Holdings a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Hemab Therapeutics Holdings discussion 0 comments